期刊文献+

“三阴”型与非“三阴”型乳腺癌患者的生物学行为差异性分析 被引量:21

Comparison of biological behavior between triple-negative breast cancer and non-triple-negative breast cancer
下载PDF
导出
摘要 目的通过回顾性分析总结"三阴"型乳腺癌与非"三阴"型乳腺癌患者的流行病学及生物学行为特点,以便为指导临床个体化治疗、判定预后奠定基础。方法收集并整理宁夏医科大学附属医院及银川市人民医院2002年1月~2004年12月收治、经病理组织学确诊,且有5年完整随访数据的乳腺癌患者231例。采用SPSS11.5统计学软件对"三阴"型与"非三阴"型乳腺癌患者的流行病学、临床病理学特点、复发转移、5年生存等方面进行分析。结果"三阴"型乳腺癌占17.3%,与非"三阴"型乳腺癌患者相比,原发肿瘤大(P〈0.05),复发转移率尤其是内脏转移率高,3年、5年生存率明显降低,其中所占比例居多的Ⅱ期及淋巴结阳性患者5年生存率也较对照组明显降低(P〈0.05)。Cox比例风险模型进行预后因素分析,本组患者发病年龄、原发肿块大小、临床分期及是否为"三阴"性表达均为乳腺癌的独立危险因素。结论"三阴"型乳腺癌与非"三阴"型乳腺癌相比,局部侵袭性强、复发转移率及内脏转移率高、预后差、生存率低"。三阴"型乳腺癌为影响乳腺癌患者预后的独立危险因素。 Objective To summarize the epidemiological and biological features of triple-negative breast cancer(TNBC) and non-triple-negative breast cancer(non-TNBC) to provide reference for devising individualized therapy and making prognostic evaluation.Methods The 5-year follow-up data were collected from 231 patients with pathologically established diagnosis of breast cancer treated in the Affiliated Hospital of Ningxia Medical University and Yinchuan People's Hospital between Jan.2002 and Dec.2004.The epidemiological and clinicopathological characteristics as well as the recurrence,metastasis and 5-year survival were compared between TNBC group and non-TNBC group.Results TNBC accounted 17.3% of the total breast cancer cases enrolled in this study.The tumor size and rates of recurrence and metastasis(especially visceral metastasis) were significantly greater in TNBC group than in non-TNBC group(P0.05).The TNBC patients showed significantly lower 3-and 5-year survival rates than the non-TNBC patients(P0.05),and TNBC patients with positive lymph nodes in clinical stage II had also a lower 5-year survival(P0.05).Cox regression model analysis identified the patients' age,primary tumor size,clinical stages and triple-negativity as the independent risk factors for breast cancer.Conclusions Compared to non-TNBC patients,patients with TNBC have higher rates of local recurrence and invasion,visceral metastasis and poorer prognosis,and a lower rate of 5-year survival.The triple negativity represents an independent factor for prognosis evaluation of breast cancer.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2011年第10期1729-1732,共4页 Journal of Southern Medical University
基金 教育部春晖计划项目(z2008-1-75006)
关键词 乳腺癌 雌激素受体 孕激素受体 人类表皮生长因子受体-2 breast cancer estrogen receptor progesterone receptor human epidermal growth factor receptor-2
  • 相关文献

参考文献15

  • 1Jema A, Seige R, Xu J, et al. Cancer statistic [J]. Cancer J Clin, 2010, 60: 277-300.
  • 2Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2011: A review of current American cancer Society guidelines and issues in cancer screening [J]. CA Cancer J Clin, 2011, 61(1): 8-30.
  • 3Irvin WJ, Carey LA. What is triple-negative breast cancer[J]. Eur J Cancer, 2008, 44: 2799-805.
  • 4Iwase H, Kurebayashi J, Tsuda H, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the registration committee of the Japanese breast cancer society[ J]. Breast Cancer, 2010, 17(2): 118-24.
  • 5Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity' in node-negative breast cancer[J]. BMC Cancer, 2008, 8: 307.
  • 6Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple- negative phenotype: a population-based study from the california cancer registry[J]. Cancer, 2007, 109(9): 1721-8.
  • 7杨德宏,刘红,赵晶.三阴型乳腺癌临床病理特征及预后分析[J].中国肿瘤临床,2008,35(9):501-504. 被引量:40
  • 8Zaha DC, Lazar E, Lazureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer [J]. Rom J Morphol Embryol, 2010, 51(1): 85-9.
  • 9Foulkes WD, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer--a reappraisal [J]. Nat Rev Clin Oncol, 2010, 7(6): 348-53.
  • 10Rakha EA, El-sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.

二级参考文献12

  • 1石毅然,曲建军,李湘洲,马世庆,王峰,王会东,张永庆,王昌亮.MUC1与HER2基因在乳腺癌中的表达及其与临床病理学指标的相关性研究[J].中国肿瘤临床,2007,34(11):621-624. 被引量:6
  • 2李孟圈,李靖若,冯宗刚,苏静,李建章.乳腺癌中BI-1基因与ER PR表达的关系及意义[J].中国肿瘤临床,2007,34(15):868-870. 被引量:2
  • 3张静,孙慧,战忠利,郝希山.雌激素受体β亚型与丝裂原活化蛋白激酶信号传导通路的相互作用机制探讨[J].中国肿瘤临床,2007,34(18):1053-1057. 被引量:4
  • 4Colleoni M,Gelber S,Goldhirsch A,et al.Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer:International Breast Cancer Study Group Trial 13-93[J].J Clin Oncol,2006,24(9):1332-1341
  • 5Pritchard KI,Shepherd LE,O'Malley FP,et al.HER2 and responsiveness of breast cancer to adjuvant chemotherapy[J].N Engl J Med,2006,354(20):2103-2111
  • 6Piccart-Gebhart MJ,Procter M,Leyland-Jones B,et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer[J].N Engl J Med,2005,353(16):1659-1672
  • 7Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets[J].Proc Natl Acad Sci U S A,2003,100(14):8418-8423
  • 8Nielsen TO,Hsu FD,Jeosen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10(16):5367-5374
  • 9Siziopikou KP,Cobleigh M.The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies[J].Breast,2007,16(1):104-107
  • 10Dent R,Trudeau M,Pritchard KI,et al.Triple-negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(15):4429-4434

共引文献39

同被引文献180

引证文献21

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部